SMIM35 Knockout cell line (U-2932) – Genotype Verified & Ready-to-use

Red cotton OmniCell bank

10000⁺

Gene Knockout Cell Lines

2000⁺

Luc/EGFP/Cas9 Tool Cell Lines

1000⁺

Wild-type Cell Lines

SMIM35 Knockout cell line (U-2932)

Copy Product Info

Catalog#

YKO-HA397462

Species

Human

Target Cell Line

U-2932

Size

1*10^6

Gene

SMIM35

Storage conditions

Shipped on dry ice; Store in liquid nitrogen

Online inquire

Overview

Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.

The U-2932 cell line was established in 1996 from the ascites of a 29-year-old female patient with diffuse large B-cell lymphoma (DLBCL), following a history of advanced-stage Hodgkin lymphoma treated with multiple chemotherapy and radiotherapy regimens. The cells belong to the activated B-cell (ABC-like) subtype of DLBCL and have been reported to overexpress BCL2, BCL6, and p53. U-2932 contains two distinct subpopulations with different surface expression patterns of CD19, CD20, and CD38, reflecting intraline heterogeneity. This human lymphoma cell line is used as a model for studying B-cell malignancies, tumor heterogeneity, molecular alterations, and therapeutic responses in diffuse large B-cell lymphoma.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.

KO Cell Construction Strategy

Adopting Red Cotton CRISPR Gene Editing Designer (www.rc-crispr.com), two sgRNAs targeting the SMIM35 gene are designed to generate a knockout strategy. The two sgRNA sequences are subsequently cloned into the EZ-editor™ vector and introduced into U-2932 cells via electroporation or lentiviral transduction. Single-cell clones are then generated using the limiting dilution method. Genomic DNA from individual clones is subjected to nucleic acid lysis and PCR amplification using the EZ-editor™ Monoclone Genotype Validation Kit (Cat# YK-MV-1000). The edited loci are further verified by Sanger sequencing to confirm the genotype. After secondary validation and quality confirmation, SMIM35 Knockout cell line (U-2932) is expanded and cryopreserved for downstream applications.

Product Overview

SMIM35 Knockout cell line (U-2932)

The SMIM35 Knockout cell line (U-2932) is generated by targeted disruption of the SMIM35 gene in U-2932 cells. This cell line is designed to investigate the role of SMIM35 in cellular function and gene regulation, as well as its potential involvement in disease-related pathways.

KO Cell Line

SMIM35 Knockout cell line (U-2932)

Gene ID

100526771

Catalog

YKO-HA397462

Gene Name

SMIM35

Product Category

Knockout(KO) Cell Line

Gene Information

NCBI

Species

Human

Mycoplasma test

Negative

Cell Morphology

Human Lymphocyte-like, suspension

Catalog Status

-

Culture method

90%RPMI-1640+10%FBS

Shipping

Cryopreserved Cells shipped in dry ice

Passage ratio

1：2-1：4

Storage Condition

Liquid nitrogen

Quality Control

All KO cell products are tested and confirmed to be free of bacterial, viral, mycoplasma contamination, and other adventitious agents.

Applications

For research use only. Not intended for use in diagnostic, therapeutic, clinical, or other applications.

Key Advantages

Easy to use

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations

High-efficient KO

These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.

Curated cells

Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Quality Control Specifications

1. Bacteria and Fungi Test

None Detected.

2. Mycoplasma test

Negative.

3. Knockout Strategy

Targeted knockout region: EExon 2

Reference Transcript: NM_001394165

Frameshift Mutation Strategy

4. STR Authentication

Download STR Report

Intended use

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use

Unpacking and Storage Instructions

1.

Cell Reception

2.

Unpacking and storage instructions

Handling procedure

1.

Cell Thawing

2.

Cell Passaging

3.

Cell cryopreservation

References

More

FAQ

Q1. How to Contact Support if Issues Arise After Receiving the KO Cells?

If any abnormalities are observed after receiving the cells, please provide the following information based on the stage of use and contact us promptly for assistance:

(1) Issues upon delivery: Please provide photos of the cells at the time of receipt along with a brief description of the issue. We will offer after-sales support accordingly.

(2) Issues after thawing or passaging: Please provide microscopic images of the cells before and after thawing/passaging, along with a detailed description of the experimental procedures. Our technical team will provide professional support.

Q2. What Information Is Required When Reporting KO Cell Product Issues?

Q3. How Should the KO cell Product Be Stored Upon Receipt?

Q4. Shipping Method

Q5. Are the Knockout Cell Lines Stable for Passaging? Is Authentication Provided?